13.17
+0.3145(+2.45%)
Currency In USD
| Previous Close | 12.86 |
| Open | 12.9 |
| Day High | 13.33 |
| Day Low | 12.88 |
| 52-Week High | 37.08 |
| 52-Week Low | 6.36 |
| Volume | 501,611 |
| Average Volume | 2.96M |
| Market Cap | 1.87B |
| PE | -3.4 |
| EPS | -3.88 |
| Moving Average 50 Days | 11.2 |
| Moving Average 200 Days | 13.98 |
| Change | 0.31 |
If you invested $1000 in Dyne Therapeutics, Inc. (DYN) since IPO date, it would be worth $551.23 as of September 16, 2025 at a share price of $13.175. Whereas If you bought $1000 worth of Dyne Therapeutics, Inc. (DYN) shares 3 years ago, it would be worth $965.16 as of September 16, 2025 at a share price of $13.175.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)
GlobeNewswire Inc.
Aug 04, 2025 11:30 AM GMT
- Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc.
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
GlobeNewswire Inc.
Jul 02, 2025 8:01 PM GMT
WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the clos
Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock
GlobeNewswire Inc.
Jul 01, 2025 1:45 AM GMT
WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pri